199 related articles for article (PubMed ID: 37519000)
1. Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
Kleiner D; Horváth IL; Bunduc S; Gergő D; Lugosi K; Fehérvári P; Hegyi P; Csupor D
Curr Neuropharmacol; 2023; 21(12):2505-2515. PubMed ID: 37519000
[TBL] [Abstract][Full Text] [Related]
2. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
3. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
[TBL] [Abstract][Full Text] [Related]
5. Effects of Sativex
Dykukha I; Essner U; Schreiber H; Raithel LM; Penner IK
Mult Scler Relat Disord; 2022 Dec; 68():104173. PubMed ID: 36174323
[TBL] [Abstract][Full Text] [Related]
6. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
8. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Haupts MR; Essner U; Mäurer M
Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
[TBL] [Abstract][Full Text] [Related]
13. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
Alessandria G; Meli R; Infante MT; Vestito L; Capello E; Bandini F
Clin Neurol Neurosurg; 2020 Sep; 196():105990. PubMed ID: 32526487
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
Fairhurst C; Kumar R; Checketts D; Tayo B; Turner S
Dev Med Child Neurol; 2020 Sep; 62(9):1031-1039. PubMed ID: 32342496
[TBL] [Abstract][Full Text] [Related]
17. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
18. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Conte A; Vila Silván C
Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Chan A; Silván CV
Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
Novotna A; Mares J; Ratcliffe S; Novakova I; Vachova M; Zapletalova O; Gasperini C; Pozzilli C; Cefaro L; Comi G; Rossi P; Ambler Z; Stelmasiak Z; Erdmann A; Montalban X; Klimek A; Davies P;
Eur J Neurol; 2011 Sep; 18(9):1122-31. PubMed ID: 21362108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]